» Articles » PMID: 35595619

Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting

Abstract

Introduction: Chimeric antigen receptor T-cell therapy (CAR T) is a revolutionary adoptive immunotherapy approach in lymphoma; however, substantial resources are necessary for administration and care of these patients. Our institution has administered tisagenlecleucel primarily in an outpatient setting, and here we report our clinical outcomes.

Patients And Methods: We conducted a single institution, retrospective study investigating outcomes of adult lymphoma patients treated with commercial tisagenlecleucel between 10/2017 and 12/2020. We analyzed patient characteristics and outcomes of efficacy and safety including overall response rate, progression-free survival, overall survival and cytokine-release syndrome, neurotoxicity, and hospitalizations.

Results: Seventy-two patients with relapsed or refractory non-Hodgkin lymphoma (NHL) who received commercial tisagenlecleucel were identified; 68 (94.4%) patients received outpatient tisagenlecleucel. The overall response rate was 43% with a complete response observed in 25 patients (34.7%). At a median follow-up of 9.1 months, the median progression-free survival was 3.3 months. Grade 3-4 cytokine release syndrome was not observed in the study group and two patients had grade 3-4 neurotoxicity. Twenty-six patients (36.1%) were admitted within 30 days after infusion with a median length of stay of 5 days. Fourteen patients (19.4%) were admitted within 72 hours of infusion. No patient died of CAR T cell-related toxicity.

Conclusion: Our experience affirms treatment with tisagenlecleucel in the outpatient setting is safe and feasible with close supervision and adequate institutional experience. After infusion, adverse events were manageable and the majority of patients did not require hospitalization.

Citing Articles

OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.

Linhares Y, Freytes C, Cherry M, Bachier C, Maris M, Hoda D Blood Adv. 2024; 8(23):6114-6126.

PMID: 39347584 PMC: 11652776. DOI: 10.1182/bloodadvances.2024013254.


Mechanisms and management of CAR T toxicity.

Ferreri C, Bhutani M Front Oncol. 2024; 14:1396490.

PMID: 38835382 PMC: 11148294. DOI: 10.3389/fonc.2024.1396490.


The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?.

Knight E T, Oluwole O, Kitko C Clin Hematol Int. 2024; 6(1):96-115.

PMID: 38817691 PMC: 11108586. DOI: 10.46989/001c.94386.


Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations.

Gatwood K, Mahmoudjafari Z, Baer B, Pak S, Lee B, Kim H Clin Hematol Int. 2024; 6(2):11-20.

PMID: 38817307 PMC: 11086991. DOI: 10.46989/001c.115793.


Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers.

Perez A, Al Sagheer T, Nahas G, Linhares Y Front Immunol. 2024; 15:1412002.

PMID: 38779668 PMC: 11109356. DOI: 10.3389/fimmu.2024.1412002.


References
1.
Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

2.
Alexander M, Culos K, Roddy J, Shaw J, Bachmeier C, Shigle T . Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. Transplant Cell Ther. 2021; 27(7):558-570. DOI: 10.1016/j.jtct.2021.01.014. View

3.
Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

4.
Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

5.
Iacoboni G, Villacampa G, Martinez-Cibrian N, Bailen R, Lopez Corral L, Sanchez J . Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 2021; 10(10):3214-3223. PMC: 8124109. DOI: 10.1002/cam4.3881. View